In particular, LEAP2 (liver-expressed antimicrobial peptide 2), an endogenous antagonist of the ghrelin receptor GHSR, has emerged as a potential target for mitigating the weight regain often observed after discontinuation of GLP-1-based therapies [22,23]
hold a published patent (WO/2021/165538) that describes compounds, wherein said compounds bind to p53 or preferably bind to p53 and inhibit the interaction of F0X04 with p53 in a cell
Whereas, Thymosin Alpha-1 is known for its strong immunostimulatory (boosts the immune system) and antiviral effects and is often used in infection-related or immunocompromised settings
Others (MOTS-c, SS-31, Tesamoerlin, Sermorelin) peptides benefit from using NaCl BAC to reduce injection site reactions, and acidic compounds such as NAD+ are best bought as a buffered version and reconstituted with NaCl BAC